Drugs / mRNA-1325
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03014089 | Dec 2016 → Jul 2019 | Zika virus infectious disease | ModernaTX, Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-07-13 | ModernaTX, Inc. | Results Publication in Cell Demonstrates Moderna’s Zika mRNA Vaccine Prevents In Utero Transmission of Zika Virus in Mice, Protects Against Zika-Related Congenital Damage modernatx.com ↗
The findings, which were published today in Cell, also demonstrated that Moderna’s Zika mRNA vaccine protected the placenta and fetus from Zika virus-induced injury. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-07-13 | ModernaTX, Inc. | Publication in Cell Demonstrates Moderna’s Zika mRNA Vaccine Prevents In Utero Transmission of Zika Virus in Mice, Protects Against Zika-Related Congenital Damage modernatx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03014089 ↗ |
| Modality | Messenger RNA (mRNA) | “two mRNA-based Zika virus vaccines (mRNA-1325 and mRNA-1893)” PMID 36682364 ↗ Jan 2023 |